Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.32
(0.53%)
INR 13.32
(0.53%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.5 Billion INR | -2.73% |
| 2022 | 9.77 Billion INR | -4.05% |
| 2021 | 10.18 Billion INR | 3.38% |
| 2020 | 9.85 Billion INR | -0.16% |
| 2019 | 9.87 Billion INR | -1.9% |
| 2018 | 10.06 Billion INR | -3.1% |
| 2017 | 10.38 Billion INR | -0.13% |
| 2016 | 10.39 Billion INR | 0.91% |
| 2015 | 10.3 Billion INR | 0.76% |
| 2014 | 10.22 Billion INR | 11.85% |
| 2013 | 9.14 Billion INR | -1.16% |
| 2012 | 9.25 Billion INR | 307.51% |
| 2011 | 2.26 Billion INR | 73.94% |
| 2010 | 1.3 Billion INR | -72.03% |
| 2009 | 4.66 Billion INR | 28.59% |
| 2008 | 3.62 Billion INR | -1.64% |
| 2007 | 3.68 Billion INR | 30.98% |
| 2006 | 2.81 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 9.5 Billion INR | 6258.73% |
| 2023 Q1 | 133.27 Million INR | -98.64% |
| 2023 FY | 9.5 Billion INR | -2.73% |
| 2023 Q3 | 149.53 Million INR | -98.44% |
| 2023 Q2 | 9.6 Billion INR | 7109.02% |
| 2022 Q3 | 138.32 Million INR | -98.64% |
| 2022 Q2 | 10.15 Billion INR | 6176.54% |
| 2022 Q4 | 9.77 Billion INR | 6966.75% |
| 2022 FY | 9.77 Billion INR | -4.05% |
| 2022 Q1 | 161.82 Million INR | -98.41% |
| 2021 FY | 10.18 Billion INR | 3.38% |
| 2021 Q4 | 10.18 Billion INR | 5245.29% |
| 2021 Q3 | 190.6 Million INR | -98.05% |
| 2021 Q1 | 289.91 Million INR | -97.06% |
| 2021 Q2 | 9.77 Billion INR | 3272.22% |
| 2020 Q2 | 10.09 Billion INR | 5926.48% |
| 2020 Q1 | 167.58 Million INR | -98.3% |
| 2020 FY | 9.85 Billion INR | -0.16% |
| 2020 Q4 | 9.85 Billion INR | 5645.71% |
| 2020 Q3 | 171.51 Million INR | -98.3% |
| 2019 Q3 | 88.64 Million INR | -99.11% |
| 2019 FY | 9.87 Billion INR | -1.9% |
| 2019 Q1 | 197.21 Million INR | -98.04% |
| 2019 Q2 | 9.94 Billion INR | 4940.84% |
| 2019 Q4 | 9.87 Billion INR | 11035.45% |
| 2018 Q1 | 36.75 Million INR | -99.65% |
| 2018 FY | 10.06 Billion INR | -3.1% |
| 2018 Q4 | 10.06 Billion INR | 0.0% |
| 2017 Q4 | 10.38 Billion INR | 0.0% |
| 2017 FY | 10.38 Billion INR | -0.13% |
| 2016 Q4 | 10.39 Billion INR | 5309.97% |
| 2016 FY | 10.39 Billion INR | 0.91% |
| 2016 Q1 | 173.89 Million INR | -98.31% |
| 2016 Q2 | 10.3 Billion INR | 5825.82% |
| 2016 Q3 | 192.18 Million INR | -98.13% |
| 2015 Q3 | 189.9 Million INR | -97.75% |
| 2015 Q4 | 10.3 Billion INR | 5325.54% |
| 2015 Q2 | 8.43 Billion INR | 4864.0% |
| 2015 FY | 10.3 Billion INR | 0.76% |
| 2015 Q1 | 169.83 Million INR | -98.34% |
| 2014 Q1 | 178.95 Million INR | -98.04% |
| 2014 Q4 | 10.22 Billion INR | 4452.27% |
| 2014 Q3 | 224.64 Million INR | -97.54% |
| 2014 FY | 10.22 Billion INR | 11.85% |
| 2014 Q2 | 9.14 Billion INR | 5010.73% |
| 2013 Q4 | 9.14 Billion INR | 2986.45% |
| 2013 FY | 9.14 Billion INR | -1.16% |
| 2013 Q3 | 296.21 Million INR | -96.8% |
| 2013 Q2 | 9.25 Billion INR | 5102.75% |
| 2013 Q1 | 177.9 Million INR | -98.08% |
| 2012 Q3 | 10.18 Billion INR | 0.0% |
| 2012 Q4 | 9.25 Billion INR | -9.2% |
| 2012 FY | 9.25 Billion INR | 307.51% |
| 2011 FY | 2.26 Billion INR | 73.94% |
| 2010 FY | 1.3 Billion INR | -72.03% |
| 2009 FY | 4.66 Billion INR | 28.59% |
| 2008 FY | 3.62 Billion INR | -1.64% |
| 2007 FY | 3.68 Billion INR | 30.98% |
| 2006 FY | 2.81 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -145.961% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -157.455% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 434.496% |
| Granules India Limited | 9.28 Billion INR | -2.388% |
| Indoco Remedies Limited | 6.47 Billion INR | -46.821% |
| Achyut Healthcare Limited | -3.74 Million INR | 253933.129% |
| Ajanta Pharma Limited | -954.9 Million INR | 1095.768% |
| Alkem Laboratories Limited | -1.6 Billion INR | 690.816% |
| Alpa Laboratories Limited | 35.36 Million INR | -26788.525% |
| Brooks Laboratories Limited | 49.48 Million INR | -19115.093% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 289.7% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -188.23% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 921.298% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 26.364% |
| Eris Lifesciences Limited | 13.8 Billion INR | 31.129% |
| FDC Limited | -57.75 Million INR | 16564.519% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 321.891% |
| Gufic Biosciences Limited | 3.19 Billion INR | -197.672% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 328.954% |
| Ipca Laboratories Limited | 11.41 Billion INR | 16.702% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 784.106% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -391.928% |
| Lasa Supergenerics Limited | 205.79 Million INR | -4520.328% |
| Laurus Labs Limited | 24.38 Billion INR | 61.006% |
| Lupin Limited | 17.19 Billion INR | 44.693% |
| Mankind Pharma Limited | -9.9 Billion INR | 195.969% |
| Medicamen Biotech Limited | 160.31 Million INR | -5831.154% |
| Medico Remedies Limited | 78.67 Million INR | -11985.602% |
| Megasoft Limited | 1.28 Billion INR | -639.65% |
| NATCO Pharma Limited | -5.81 Billion INR | 263.462% |
| Piramal Pharma Limited | 42.27 Billion INR | 77.508% |
| RPG Life Sciences Limited | -364.7 Million INR | 2707.236% |
| Sigachi Industries Limited | 859.94 Million INR | -1005.715% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 113.121% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -6458.733% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -20476.462% |
| Unichem Laboratories Limited | 931.91 Million INR | -920.327% |
| Wanbury Limited | 1.1 Billion INR | -759.825% |
| Windlas Biotech Limited | -273.04 Million INR | 3582.489% |
| ZIM Laboratories Limited | 983.6 Million INR | -866.709% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -143.062% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 1109.619% |
| Divi's Laboratories Limited | -39.77 Billion INR | 123.909% |
| Hester Biosciences Limited | 2.29 Billion INR | -315.088% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 504.965% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 3921.903% |
| Bal Pharma Limited | 1.26 Billion INR | -652.523% |
| Strides Pharma Science Limited | 23.25 Billion INR | 59.115% |
| Venus Remedies Limited | -267.7 Million INR | 3651.957% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -264.049% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -54.428% |
| Shilpa Medicare Limited | 9.06 Billion INR | -4.841% |
| Aarti Drugs Limited | 5.54 Billion INR | -71.375% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 963.397% |
| Suven Life Sciences Limited | -1.63 Billion INR | 682.385% |
| Valiant Laboratories Limited | -295.03 Million INR | 3322.901% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -237.041% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 5.189% |
| Themis Medicare Limited | 764.96 Million INR | -1143.015% |
| Hikal Limited | 7.96 Billion INR | -19.35% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 70.127% |
| Sequent Scientific Limited | 4.17 Billion INR | -127.553% |
| Novartis India Limited | -5.89 Billion INR | 261.406% |
| Wockhardt Limited | 18.27 Billion INR | 47.955% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 64.877% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 51648.244% |
| Neuland Laboratories Limited | -214.05 Million INR | 4542.062% |
| Morepen Laboratories Limited | -231.17 Million INR | 4213.174% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -7821.25% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -874.429% |